Maky Zanganeh and Dave Gancarz share their take on the result, which at the topline showed that Ivonescimab plus chemo reduced the risk of death by 34% vs the PD-1 Tislelizumab plus chemo, and they are given the opportunity to respond to some of the pushback heard around McCormick Place.